Dendritic Cell Immunotherapy Failed to Gain Upper Hand in Relapsed, Refractory Myeloma in Study
A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase 1 trial (NCT02248402) of…
News
Targeting Genetic Alterations in Multiple Myeloma May Suppress Tumor Growth, Study Suggests
Changes in gene activity in the DNA of multiple myeloma cells can lead to the progression of the disease by shutting down the expression of…
Janssen and BMS to Test Darzalex, Opdivo Combo in Multiple Myeloma and Solid Tumors
Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma…
Myeloma Triple Combo Treatment Found Superior to Standard Therapy in Phase 3 Trial
Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and…
Myeloma Resistance to Proteasome Inhibitors May Boost Sensitivity to Other Drug Classes
Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…
CTCA Hospitals Enrolling Myeloma, Other Cancer Patients, in TAPUR Clinical Trial
Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.
Triple-Combo Treatment of Smoldering Multiple Myeloma May Stall Disease Progression
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
Specialty US Pharmacy, Diplomat, to Dispense Darzalex Combo to Advanced Myeloma Patients
The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or…
Aduro Presents Positive Results on BION-1301 for Treating Multiple Myeloma
Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other…
2 Common Additions to Multiple Myeloma Therapy Don’t Offer Added Benefit, Study Says
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
